Bigmar, Inc. - BGMR- Profile

Bigmar, Inc.. The Group's principal activity is to manufacture and market generic pharmaceutical Oncology products and intravenous infusion solutions. It operates through three wholly owned subsidiaries: Bioren SA (Bioren), Bigmar Pharmaceuticals SA (Pharmaceuticals) and Bigmar Therapeutics (Therapeutics). Bioren manufactures and markets 22 types of intravenous infusion solutions and other related products. Pharmaceuticals segment manufactures and markets Oncology Products including Calcium Leucovorin, Sodium Folinate, Dacarbazine, Doxorubicin, Etoposide, Fluorouracil and Cisplatin. The Oncology Products are marketed in the United States, Italy, Germany, Switzerland, Brazil, Greece and Spain. The pharmaceutical products are generally sold directly to distributors, wholesalers, health care facilities and government agencies. At 31-Dec-2000, Therapeutics has no significant business operations. Intravenous solutions accounted for 78% of 2000 revenues and Pharmaceuticals, 22%. Intravenous solutions accounted for 78% of 2000 revenues and Pharmaceuticals, 22%